Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CNTB Connect Biopharma	$2.05 -4.7%	$1.52	$0.51 ▼ $2.86	$114.23M	-0.09	222,577 shs	152,118 shs
ITOS iTeos Therapeutics	$10.11	$10.11	$4.80 ▼ $18.13	$446.91M	1.49	1.64 million shs	1.47 million shs
KMDA Kamada	$7.35 +0.7%	$7.46	$5.17 ▼ $9.15	$422.66M	0.93	50,957 shs	25,607 shs
KOD Kodiak Sciences	$10.57 +5.3%	$5.58	$1.92 ▼ $11.60	$558.33M	2.41	661,366 shs	1.59 million shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CNTB Connect Biopharma	0.00%	-0.97%	+10.22%	+172.97%	+75.21%
ITOS iTeos Therapeutics	0.00%	0.00%	-1.46%	+29.45%	-32.96%
KMDA Kamada	0.00%	+3.23%	-1.08%	+5.91%	+37.90%
KOD Kodiak Sciences	0.00%	+33.80%	+103.66%	+202.00%	+314.51%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CNTB Connect Biopharma	3.3052 of 5 stars	3.8	5.0	0.0	2.2	2.5	0.0
ITOS iTeos Therapeutics	2.9772 of 5 stars	3.1	3.0	0.0	2.8	3.3	0.6
KMDA Kamada	4.6352 of 5 stars	3.3	5.0	0.0	3.2	1.7	4.4
KOD Kodiak Sciences	2.4327 of 5 stars	1.0	1.0	4.6	2.5	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CNTB Connect Biopharma	3.50	Strong Buy	$7.00	241.46% Upside
ITOS iTeos Therapeutics	2.14	Hold	$15.50	53.31% Upside
KMDA Kamada	2.67	Moderate Buy	$13.00	76.87% Upside
KOD Kodiak Sciences	2.00	Hold	$11.25	6.43% Upside

Current Analyst Ratings Breakdown

Latest CNTB, ITOS, KOD, and KMDA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2025	KOD Kodiak Sciences	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Underweight ➝ Underweight	$4.00 ➝ $7.00
8/14/2025	KOD Kodiak Sciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underweight ➝ Neutral	$15.00
8/13/2025	CNTB Connect Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00
8/7/2025	ITOS iTeos Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$12.00 ➝ $11.00
7/22/2025	CNTB Connect Biopharma	Northland Capmk Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/21/2025	ITOS iTeos Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/21/2025	ITOS iTeos Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$12.00 ➝ $10.50
6/12/2025	CNTB Connect Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy ➝ Buy	$7.00
5/28/2025	ITOS iTeos Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$13.00 ➝ $12.00
5/28/2025	ITOS iTeos Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$10.00 ➝ $12.00

(Data available from 8/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CNTB Connect Biopharma	$1.97M	58.13	N/A	N/A	$1.28 per share	1.60
ITOS iTeos Therapeutics	$35M	12.77	N/A	N/A	$11.17 per share	0.91
KMDA Kamada	$160.95M	2.63	$0.49 per share	14.95	$4.52 per share	1.63
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	$1.33 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CNTB Connect Biopharma	-$15.63M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	9/5/2025 (Estimated)
ITOS iTeos Therapeutics	-$134.41M	-$4.67	N/A	N/A	N/A	N/A	-33.26%	-28.16%	N/A
KMDA Kamada	$14.46M	$0.34	21.62	22.97	0.78	11.22%	7.41%	5.18%	N/A
KOD Kodiak Sciences	-$176.21M	-$3.80	N/A	N/A	N/A	N/A	-155.27%	-63.29%	N/A

Latest CNTB, ITOS, KOD, and KMDA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/5/2025	H1 2025	CNTB Connect Biopharma	-$0.22	N/A	N/A	N/A	N/A	N/A
8/13/2025	Q2 2025	KMDA Kamada	$0.09	$0.13	+$0.04	$0.13	$158.59 million	$44.75 million
8/13/2025	Q2 2025	KOD Kodiak Sciences	-$1.01	-$1.03	-$0.02	-$1.03	N/A	N/A
8/6/2025	Q2 2025	ITOS iTeos Therapeutics	-$1.12	-$1.51	-$0.39	-$1.81	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CNTB Connect Biopharma	N/A	N/A	N/A	N/A	N/A
ITOS iTeos Therapeutics	N/A	N/A	N/A	N/A	N/A
KMDA Kamada	N/A	N/A	N/A	N/A	N/A
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CNTB Connect Biopharma	0.01	7.24	10.25
ITOS iTeos Therapeutics	N/A	7.53	7.53
KMDA Kamada	N/A	4.00	1.93
KOD Kodiak Sciences	N/A	3.48	4.62

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CNTB Connect Biopharma	58.72%
ITOS iTeos Therapeutics	97.16%
KMDA Kamada	20.38%
KOD Kodiak Sciences	89.06%

Insider Ownership

Company	Insider Ownership
CNTB Connect Biopharma	22.60%
ITOS iTeos Therapeutics	14.20%
KMDA Kamada	36.10%
KOD Kodiak Sciences	45.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CNTB Connect Biopharma	110	55.72 million	43.13 million	Optionable
ITOS iTeos Therapeutics	90	44.21 million	37.93 million	Optionable
KMDA Kamada	360	57.51 million	36.75 million	Optionable
KOD Kodiak Sciences	90	52.82 million	28.58 million	Optionable

CNTB, ITOS, KOD, and KMDA Headlines

Recent News About These Companies

Kodiak Sciences (NASDAQ:KOD) Shares Up 8.4% - Here's Why

4 hours ago | marketbeat.com

Kodiak Sciences (NASDAQ:KOD) Stock Rating Upgraded by JPMorgan Chase & Co.

August 17 at 3:31 AM | americanbankingnews.com

Kodiak Sciences (NASDAQ:KOD) Shares Gap Up - Time to Buy?

August 16 at 12:09 PM | marketbeat.com

Kodiak Sciences (NASDAQ:KOD) Rating Increased to Neutral at JPMorgan Chase & Co.

August 16 at 8:21 AM | marketbeat.com

XTX Topco Ltd Acquires New Stake in Kodiak Sciences Inc. (NASDAQ:KOD)

August 16 at 3:18 AM | marketbeat.com

JP Morgan Upgrades Kodiak Sciences (KOD)

August 15 at 4:05 AM | msn.com

Kodiak Sciences Inc.: Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2025 Financial Results

August 14 at 6:03 PM | finanznachrichten.de

Kodiak Sciences price target raised to $7 from $4 at Barclays

August 14 at 1:02 PM | msn.com

Kodiak Q2 Loss Wider Than Expected, Pipeline Development in Focus

August 14 at 12:46 PM | zacks.com

Kodiak Sciences Reports Q2 2025 Financial Results and Clinical Progress

August 14 at 8:01 AM | msn.com

Kodiak Sciences reports Q2 EPS ($1.03), consensus ($1.05)

August 13, 2025 | msn.com

Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2025 Financial Results

August 13, 2025 | prnewswire.com

Federated Hermes Inc. Acquires Shares of 84,006 Kodiak Sciences Inc. (NASDAQ:KOD)

August 11, 2025 | marketbeat.com

Kodiak Sciences (KOD) to Release Quarterly Earnings on Wednesday

August 11, 2025 | americanbankingnews.com

Kodiak Sciences (KOD) to Release Earnings on Wednesday

August 6, 2025 | marketbeat.com

Kodiak Sciences Inc. (NASDAQ:KOD) Shares Bought by GSA Capital Partners LLP

August 4, 2025 | marketbeat.com

Kodiak Sciences Inc. (KOD) Stock Price Today - WSJ

July 25, 2025 | wsj.com

Tsunami alerts for Alaska canceled after 7.3-magnitude earthquake off Aleutians

July 18, 2025 | msn.com

Part 1: Johnson recounts PTSD treatment after May breakdown

July 17, 2025 | kodiakdailymirror.comK

Enduring the heat of California

July 15, 2025 | kodiakdailymirror.comK

Penny Stocks To Watch In July 2025

July 11, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTB, ITOS, KOD, and KMDA Company Descriptions

Connect Biopharma NASDAQ:CNTB

$2.05 -0.10 (-4.65%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$2.12 +0.07 (+3.37%)

As of 08/15/2025 05:24 PM Eastern

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.

iTeos Therapeutics NASDAQ:ITOS

$10.11 0.00 (0.00%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$10.11 0.00 (0.00%)

As of 08/15/2025 05:36 PM Eastern

iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.

Kamada NASDAQ:KMDA

$7.35 +0.05 (+0.68%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$7.38 +0.03 (+0.41%)

As of 08/15/2025 06:35 PM Eastern

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

Kodiak Sciences NASDAQ:KOD

$10.57 +0.53 (+5.28%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$10.11 -0.46 (-4.34%)

As of 08/15/2025 07:20 PM Eastern

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time